Click on image to view larger version.

Figure 2 Proportion of Patients Treated With Abciximab Versus Eptifibatide in a Given Hospital

Denominator reflects all patients undergoing primary percutaneous coronary intervention (PCI) at the hospital. There was wide variation in the relative use of abciximab versus eptifibatide across the participating hospitals. Although all hospitals use eptifibatide, abciximab use ranged from 0 to 56.7% of patients undergoing primary PCI.